AdaptHealth (NASDAQ:AHCO) Given New $16.00 Price Target at Robert W. Baird

AdaptHealth (NASDAQ:AHCO) had its target price upped by Robert W. Baird from $14.00 to $16.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other equities analysts have also issued reports on AHCO. Truist Financial increased their target price on AdaptHealth from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday. Canaccord Genuity Group increased their target price on AdaptHealth from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday. Royal Bank of Canada increased their price target on AdaptHealth from $11.00 to $14.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, UBS Group reduced their price target on AdaptHealth from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, AdaptHealth currently has an average rating of “Buy” and an average price target of $13.80.

AdaptHealth Price Performance

AHCO opened at $11.09 on Thursday. The stock’s 50-day moving average price is $9.89 and its 200 day moving average price is $10.22. AdaptHealth has a 12-month low of $8.35 and a 12-month high of $11.90. The company has a current ratio of 1.24, a quick ratio of 1.00 and a debt-to-equity ratio of 1.34. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -6.72, a PEG ratio of 1.08 and a beta of 1.12.

Institutional Investors Weigh In On AdaptHealth

A number of hedge funds have recently bought and sold shares of AHCO. Intech Investment Management LLC increased its holdings in shares of AdaptHealth by 223.2% in the 3rd quarter. Intech Investment Management LLC now owns 59,650 shares of the company’s stock valued at $670,000 after acquiring an additional 41,196 shares during the last quarter. Victory Capital Management Inc. increased its holdings in shares of AdaptHealth by 727.4% in the 3rd quarter. Victory Capital Management Inc. now owns 141,507 shares of the company’s stock valued at $1,589,000 after acquiring an additional 124,404 shares during the last quarter. Royce & Associates LP increased its holdings in shares of AdaptHealth by 13.5% in the 3rd quarter. Royce & Associates LP now owns 777,405 shares of the company’s stock valued at $8,730,000 after acquiring an additional 92,740 shares during the last quarter. Barclays PLC increased its holdings in shares of AdaptHealth by 361.3% in the 3rd quarter. Barclays PLC now owns 181,240 shares of the company’s stock valued at $2,034,000 after acquiring an additional 141,949 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in shares of AdaptHealth by 39.7% in the 3rd quarter. Principal Financial Group Inc. now owns 543,744 shares of the company’s stock valued at $6,106,000 after acquiring an additional 154,434 shares during the last quarter. Institutional investors and hedge funds own 82.67% of the company’s stock.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.